About MALLINCKRODTMallinckrodt is a global company made up of several 100% subsidiaries that develop, manufacture, market and market specific pharmaceutical products and therapies. The main priorities of the company`s special fire segment are autoimmune and rare diseases in specialized fields such as neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and intensive neonatal respiratory treatments; Analgesics and gastrointestinal products. The reportable specialty generics segment includes generic special medicines and active pharmaceutical substances. To learn more about Mallinckrodt, visit www.mallinckrodt.com. The conclusion of these agreements, the elements of which Mallinckrodt is already implementing, is part of the solution to this epidemic in the field of public health. The Mallinckrodt colony is emblematic of the government`s continued verification of pharmaceutical marketing and comes shortly after the DOJ received its largest opioid-related colony this summer. In July 2019, the DOJ entered into a $1.4 billion transaction with Reckitt Benckiser Group plc (RB Group) to resolve FCA`s claims related to the commercialization of Suboxone, an opioid intended to reduce opioid withdrawal symptoms. This transaction included the loss of $647 million in revenue for the settlement of criminal liability under a non-prosecution agreement and $700 million for the settlement of civil liability (up to $200 million of this amount being reserved for States that opt for the transaction). The comparison relates to allegations that a former subsidiary of RB Group misled suppliers and payers by marketing Suboxone as “less preventable and less abusive and safer for children, families and communities” than competing drugs, without basis for such claims. The agreement — and a separate agreement with the Federal Trade Commission — also addresses allegations that RB Group`s subsidiary falsely stated that it had discontinued a form of Suboxone tablets for safety reasons, when, according to the government, this attitude was intended to “delay suboxone`s generic entry into competition.” .